贝瑞基因(000710) - 2018 Q3 - 季度财报(更新)

Financial Performance - Operating revenue for the reporting period was ¥383,743,362.77, reflecting a year-on-year growth of 31.47%[7] - Net profit attributable to shareholders rose by 34.63% to ¥93,108,949.06[7] - The net profit after deducting non-recurring gains and losses was ¥93,000,745.33, up 37.51% year-on-year[7] - The basic earnings per share increased by 27.69% to ¥0.2596[7] - Total operating revenue for Q3 2018 reached ¥383.74 million, an increase of 31.5% compared to ¥291.89 million in the same period last year[44] - Net profit for Q3 2018 was ¥92.05 million, up 27.7% from ¥72.08 million in Q3 2017[45] - Total operating revenue for the current period was CNY 983,092,106.56, compared to CNY 704,516,027.86 in the previous period, marking an increase of approximately 39.5%[60] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,021,056,065.13, an increase of 11.88% compared to the previous year[7] - The total assets of Chengdu Beirui and Kang Gene Technology Co., Ltd. reached approximately CNY 2.02 billion as of September 30, 2018, compared to CNY 1.81 billion at the beginning of the period, reflecting an increase of about 11.85%[36] - The company's non-current assets totaled CNY 714.06 million, a slight increase from CNY 703.69 million, reflecting a growth of about 1.9%[37] - The total liabilities decreased from CNY 1.02 billion to CNY 1.01 billion, showing a reduction of approximately 0.98%[37] - Total liabilities decreased to ¥1.40 billion from ¥12.38 billion, indicating a significant reduction in short-term liabilities[42] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥85,275,979.85, a significant increase of 608.46%[7] - Operating cash flow generated was CNY 85,275,979.85, a recovery from a negative cash flow of CNY -16,771,441.89 in the prior period[62] - The net cash flow from investing activities was -$30,006,523.00, a sharp decline from $329,662,289.03 in the previous period[66] - The total cash and cash equivalents at the end of the period were $99,681,971.20, down from $236,009,678.85 in the previous period, reflecting a decrease of about 57.77%[66] Expenses - Operating costs increased by 38.50% year-on-year, attributed to higher material and labor costs due to increased business volume[16] - Income tax expenses increased by 125.22% year-on-year, reflecting higher tax provisions due to business growth[17] - R&D expenses increased by 111.68% year-on-year, as the company intensified investment in the full industry chain of genetic testing[21] - Research and development expenses surged to ¥26.85 million, a significant increase of 307.5% compared to ¥6.59 million in the previous year[45] - The total cost of operations for Q3 2018 was ¥280.46 million, an increase of 30.1% from ¥215.55 million in the same period last year[44] Shareholder Information - Net assets attributable to shareholders increased by 16.86% to ¥1,795,632,271.63[7] - The top ten shareholders held a combined 70.56% of the company's shares, with the largest shareholder owning 14.55%[11] - The company reported a total comprehensive income of CNY 92,783,760.16, compared to CNY 72,080,280.37 in the prior period[50] Other Information - The company decided to terminate the investment in US Baina Gene Co., Ltd. due to regulatory uncertainties, which will not adversely affect its financial status or operating results[22] - The company plans to raise up to RMB 400 million through debt financing to support the construction of the Gene Big Data Center project[23] - The company reported no derivative investments during the reporting period, indicating a conservative investment strategy[28] - There were no instances of non-compliance with external guarantees during the reporting period, reflecting sound financial governance[30] - The report for the third quarter was not audited, which may affect the reliability of the financial data presented[67]